Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Predictors for cancer treatment

A cancer treatment, cancer technology, applied in the direction of microbial determination/testing, drug combination, measuring device, etc., can solve problems such as harmful treatment options, narrow therapeutic index and toxicity

Inactive Publication Date: 2014-07-16
JANSSEN PHARMA NV
View PDF25 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the narrow therapeutic index of many existing cancer treatments and the potential role of toxicity, such differential responses have the potential to result in patients undergoing unnecessary, ineffective and potentially harmful treatment regimens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Predictors for cancer treatment
  • Predictors for cancer treatment
  • Predictors for cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0039] Non-Hodgkin’s Lymphoma (NHL) covers a variety of unique malignant lymphoid entities, which vary in clinical manifestations, morphological appearance, immunology, and molecular phenotypes. Follicular lymphoma (FL) is the most common type of indolent NHL, and some patients with a very slow course show similar degrees of variability, while others develop and die within only 5 years (Dave 2004). A randomized, open-label, positive-controlled, multi-center, multi-country, prospective study was carried out for the combination of bortezomib and rituximab (Vc-R) and single The efficacy and safety of the dosage form of rituximab were compared in subjects with relapsed or refractory rituximab naive or sensitive follicular B cell NHL.

[0040] The subjects were randomly assigned to treatment group A (Vc-R) or B (rituximab) at a ratio of 1:1, considering the following stratification factors:

[0041] ·Follicular lymphoma International Prognostic Index (FLIPI) score (low [0 or 1 factor],...

example 2

[0160] The single predictors associated with the positive response are shown in Table 5.

[0161]

example 3

[0163] The predictor group pairs associated with the positive response are shown in Tables 6 and 7.

[0164]

[0165]

[0166]

[0167] Arif A(2009), Jamal S, Mushtaq S, Ahmed S, Mubarik A. Frequency of bc1-2gene rearrangement in B-Cell Non-Hodgkin’s lymphoma. Asian Pacific J Cancer Prev2009; 10(2): 237-240.

[0168] Binstadt BA (2003), Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111(4): 697-703.

[0169] Cartron G (2002), Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood2002; 99(3): 754-758.

[0170] Chen P (1996), Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996; 86: 961-972.

[0171] Chen S (2010), Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMBl (PI 1A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.

Description

[0001] Cross reference to related patent applications [0002] This patent application requires the priority of provisional application serial number 61 / 522,596 filed on August 11, 2011 and provisional application serial number 61 / 560,555 filed on November 16, 2011, both of which are incorporated by reference in their entirety In this article. Technical field [0003] This application relates to the treatment of cancer patients. Background technique [0004] Despite progress in the development of successful cancer treatments, only a small group of patients respond to any particular treatment. Due to the narrow therapeutic index and potential effects of toxicity in many existing cancer treatments, such different responses may cause patients to experience unnecessary, ineffective, and possibly harmful treatment options. [0005] One way to optimize treatment to treat an individual patient is to determine whether the patient has one or more predictors that correlate with specific conse...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57407G01N2800/52A61K31/19A61K31/198A61K31/573A61K31/69A61P35/00A61P35/02A61K2300/00A61K31/4965G01N33/574A61K31/196A61K39/39558C12Q1/6886G01N33/92
Inventor D.里西W.李E.D.赫尼茨
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com